Genomic study of metabolic fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 70 years old.
- If you have MASLD, you need advanced liver scarring (stage 2 or more) or a liver cancer diagnosis.
- If you are in the control group, you must be a blood donor who is overweight or obese and have at least two of the following: high blood sugar/diabetes, high cholesterol, or high blood pressure.
- You cannot have chronic viral hepatitis (Hepatitis B or C) or other liver diseases like hemochromatosis or Wilson's disease.
- You must be enrolled in another study (SERENA or REASON) if you have MASLD.
- You must have had a liver biopsy or gallbladder removal for the MASLD group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study examines blood and tissue samples from people with HIV, people without HIV, and healthy volunteers to understand how fatty liver disease develops and progresses. Researchers hope to find new ways to detect and treat fatty liver disease, especially in people living with HIV.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.